Dr Reddy's lowers price of cardiovascular drug Cidmus to widen brand access

Dr Reddy's Laboratories announced on Wednesday that the price of its cardiovascular drug Cidmus has been slashed. The medication is a combination of sacubitril and valsartan that is prescribed to people who have heart failure.

Cidmus tablets are available in three strengths: 50mg, 100mg, and 200mg, and should be taken twice a day.

Cidmus will now be priced at Rs29 for 50 mg (down from Rs78.32), Rs49 for 100 mg (down from Rs83.86), and Rs79 for 200 mg (down from Rs96.71) per tablet, according to a statement from the Hyderabad-based drugmaker.

This price cut will broaden access to this trusted and well-established brand, it added.

In 2022, Dr Reddy's acquired Novartis AG's Cidmus brand for the Indian market.

At around 10.10 AM, Dr Reddy’s was trading 0.12% lower at Rs4,359.10 per piece, against the previous close of Rs4,364.35 on NSE. The counter hit an intraday high and low of Rs4,383.15 and Rs4,353.50 respectively.

For feedback and suggestions, write to us at editorial@iifl.com